Brainfirst training institutes brain-learning platform aims to ‘help people with cognitive disabilities’

The Brainfirst Brain Training Institute is aiming to provide “brain training” to people with “learning and memory problems” in a move that is said to be a major leap forward for the field.

The BrainFirst Brain Training institute is aiming for “brain-learning” platforms that can be used by people with disabilities.

“The BrainFirst is the brain-training platform that was created for the development of brain-based devices that could be used to improve memory and cognitive abilities,” said co-founder and CEO Mark Williams.

The company says it aims to create the technology that could enable people with dementia, autism and other learning disabilities to improve their daily lives, by using a “smart” computer to help with their everyday tasks.

BrainFirst said it was developing the platform, which would offer people with a “learning disability” with “memory problems”, as well as those with “speech, language, and language processing problems”.

It will be available for “early-stage research”, it said.

Its aim is to have the technology available within the next 10 years.

Researchers are using a smart phone to help people with learning disabilities improve their skills at work and school, with the aim of helping them “make better use of the technology”.

Researchers have also been using the technology to help those with dementia and autism improve their speech and language skills.

It comes as Australia is poised to become the first country to ban the use of electroshock therapy in people with mental health issues, in a bid to reduce the spread of the disease.

Research has shown that electroshock can cause “brain damage”, with studies showing that it can also damage brain cells.

This is despite the fact that it has been shown to be effective in treating people with schizophrenia, bipolar disorder, depression, epilepsy and autism.

Last month, it was reported that research had shown that the treatment could prevent people with Alzheimer’s disease from developing dementia.

In addition, research has shown the treatment was safe for people with Parkinson’s disease.